← Leaderboards
Yong Teng
Emory University
$3,881,194
Attributed
$4,045,216
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $758.4K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,045,216 · 5
By mechanism
R01$3,411,172 · 3
R03$634,044 · 2
Top collaborators
- Zhengjia Chen2 shared
Most similar at Emory University
Same institution · by research overlap
- Nabil F Saba$1,960,185
- Sunil Sudhir Raikar$1,320,662
- Zhengjia Chen$164,022
- Matthew James Magee$4,633,632
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingMolecularTumorHead And Neck CancerEpidermal Growth Factor ReceptorSignal TransductionTargeted TreatmentUnited States National Institutes Of HealthNanoparticleTumor ProgressionTreatment EfficacyMalignant NeoplasmsResponseToxic EffectPre-ClinicalComplexOverexpressionPathway InteractionsProteinsInsightIn VitroMalignant Epithelial CellEffective TherapyDesign
Grant awards (14)
Inhibiting mitochondrial complex I to improve cetuximab efficacy in oral cancer$378,951
R01 · FY2025 · DE · contact PI
Targeted Arf1 inhibition to enhance immune response in oral cancer$371,905
R01 · FY2025 · DE · contact PI
Inhibiting mitochondrial complex I to improve cetuximab efficacy in oral cancer$386,463
R01 · FY2024 · DE · contact PI
Targeted Arf1 inhibition to enhance immune response in oral cancer$371,905
R01 · FY2024 · DE · contact PI
ATAD3A as a Novel Target in Head and Neck Cancer$379,246
R01 · FY2023 · DE · contact PI
Role of FAT1 somatic mutations in aggressiveness of head and neck cancer$158,796
R03 · FY2023 · DE · contact PI
ATAD3A as a Novel Target in Head and Neck Cancer$380,464
R01 · FY2022 · DE · contact PI
Role of FAT1 somatic mutations in aggressiveness of head and neck cancer$169,248
R03 · FY2022 · DE · contact PI
ATAD3A as a Novel Target in Head and Neck Cancer$402,167
R01 · FY2021 · DE · contact PI
ATAD3A as a Novel Target in Head and Neck Cancer$369,447
R01 · FY2020 · DE · contact PI
The Impact of Arf1 on Hypoxia Signaling and Oral Cancer$82,466
R03 · FY2020 · DE · contact PI
The Impact of Arf1 on Hypoxia Signaling and Oral Cancer$71,034
R03 · FY2020 · DE · contact PI
ATAD3A as a Novel Target in Head and Neck Cancer$370,624
R01 · FY2019 · DE · contact PI
The Impact of Arf1 on Hypoxia Signaling and Oral Cancer$152,500
R03 · FY2019 · DE · contact PI